Arcellx

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

REDWOOD CITY, Calif. , Feb. 29, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, at 2:50 p.m.

Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference

Arcellx, Inc. (ACLX) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of a loss of $0.63 per share. This compares to loss of $0.76 per share a year ago.

Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates

-- Expanded strategic partnership with Kite -- -- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory multiple myeloma -- -- Ended the quarter with $729.2M, extending cash runway into 2027 -- REDWOOD CITY, Calif. , Feb. 28, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2023.

Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights

ADC Therapeutics

Viking Therapeutics

Following a hot year of M&A with biotech stocks, we'll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between now and 2028, pharmaceutical giants stand to lose billions in revenue as blockbuster drug patents expire.

The 3 Biotech Stocks That Could Make Your February Unforgettable

The company's lead product candidate, CART-ddBCMA, has shown potential as a game-changing strategy for the treatment of relapsed or refractory multiple myeloma.

Arcellx: Navigating The CAR T-Cell Revolution

Beam Therapeutics

Regeneron Pharmaceuticals

Biotech stocks, and the sector in general, saw a widespread beat down over the past two years. Venture capital dried up, post-pandemic healthcare landscapes shifted, and regulatory clampdowns tightened already-slim margins.

Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market

CRISPR Therapeutics

Revolution Medicines

The pharma stock leaders can at times seem overly risk averse with their approach to developing new medicines and cures. With the difficulty of clinical trials and the uncertainty of Federal Drug Administration (FDA) approval, many pharma companies prefer to play it safe rather than bet big.

Pharma's Frontline: 3 Stocks Driving Revolutionary Drug Development

-- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA (anito-cel) infusion of 26.5 months – -- The estimated median progression free survival by Kaplan-Meier is 28 months -- -- Oral presentation at ASH will be on Monday, December 11, 2023 at 5 p.m. PT -- -- Company to host a live webcast event with an expert panel of clinicians on Monday, December 11 at 8 p.m.

Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH

Vertex Pharmaceuticals

In the dynamic realm of modern medicine, biotech stocks have effectively emerged at the forefront of a transformation. These innovative players are steering us towards a new era of medical marvels with precision and personalization.

3 Biotech Stocks That Could Be Multibaggers in the Making

Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.

Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead

Arcellx's CART-ddBCMA reported strong and competitive data in late-line multiple myeloma patients, positioning it well against CAR-T leader Carvykti. The updated data at ASH show that the efficacy held up and even slightly improved compared to the previous update, and good safety. The partnership with Gilead Sciences provides a cash infusion and de-risks CART-ddBCMA's manufacturing process.

Arcellx: A Strong Contender In The CAR-T Multiple Myeloma Market

Gilead Sciences

Arcellx Inc (NASDAQ:ACLX) shares jumped 8% to $51.28 in early Wednesday trading after the clinical-stage biotechnology company announced that it has received a $200 million equity investment from Gilead Sciences Inc's Kite as part of an expanded collaboration.     Gilead will buy 3.24 million shares of Arcellx at a price of $61.68 per share, representing a 30% premium to Tuesday's closing price.

Arcellx stock climbs on Gilead investment

Arcellx and Gilead's Kite division deepened their collaboration in cancer treatments on Wednesday, and ACLX stock rocketed into a breakout.

Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead

Shares of Arcellx Inc. ACLX, +4.33% were set to surge Wednesday, after biotechnology company announced a $200 million equity investment by Gilead Sciences Inc.'s GILD, -0.28% Kite as part of an expanded collaboration. Under terms of the investment, Gilead will buy 3.24 million Arcellx shares for $200 million, which will give Gilead a 13% stake in Arcellx, and extend Arcellx's cash runway into 2027.

Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium

SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced that the companies have expanded their existing collaboration, which was originally announced in December 2022. Kite has exercised its option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, in multiple myeloma, which is comprised of ARC-T cells and SparX proteins that target BCMA. The companies have also expanded the scope of th.

Kite and Arcellx Announce Expansion in Strategic Partnership

-- Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment -- -- Kite exercises option to Arcellx's ARC-SparX program ACLX-001 in multiple myeloma -- -- The companies expand the scope of their existing collaboration for CART-ddBCMA to include lymphomas -- REDWOOD CITY, Calif. and SANTA MONICA, Calif.

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

-- Recently released ASH abstract for the company's Phase 1 CART-ddBCMA trial demonstrated that median duration of response, progression free survival, and overall survival not reached with median follow-up of 22 months after CART-ddBCMA infusion -- -- Company to present new patient data from its Phase 1 CART-ddBCMA trial during an oral presentation with a median follow-up of 26.5 months at the 65th ASH Annual Meeting in December -- REDWOOD CITY, Calif., Nov. 13, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the third quarter ended September 30, 2023 and provided recent business highlights.

Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights

Arcellx (ACLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Arcellx (ACLX) This Earnings Season?

Eyenovia

Gracell Biotechnologies

Legend Biotech

Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

Here is how Arcellx, Inc. (ACLX) and Ardelyx (ARDX) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Arcellx (ACLX) This Year?

-- Abstract released today is from a June 2, 2023 data cut -- -- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA infusion of 22 months -- -- A more recent data cut will be shared during the oral presentation with a median follow-up of 26.5 months -- -- Company to host a live webcast event with an expert panel of clinicians -- REDWOOD CITY, Calif. , Nov. 2, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12, 2023 in San Diego, California.

Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition

Apogee Therapeutics Inc

Immunome

Nuvalent

Prime Medicine Inc

Vir Biotechnology

Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.

7 Biotech Stocks to Get In Now Before Investors Catch On

Here is how Arcellx, Inc. (ACLX) and BellRing Brands (BRBR) have performed compared to their sector so far this year.

Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year?

Bristol-Myers

Autologous chimeric antigen receptor T cell therapy is 0ne of the most promising, relatively new types of cancer treatments. CAR T involves “reprogramming” patients' T cells, which fight hostile cells within the body.

Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs

The average of price targets set by Wall Street analysts indicates a potential upside of 35.6% in Arcellx, Inc. (ACLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

News for Arcellx Stock (ACLX)